Publications by authors named "Amy Hankin"
Article Synopsis
- Lynch syndrome (LS) is linked to increased risks of colorectal and endometrial cancers, but its association with other cancers like prostate cancer is being explored.
- Screening for prostate cancer can be tricky due to potential genetic risks, which complicates the development of clear guidelines.
- A case study suggests that combining immune checkpoint inhibitors with androgen deprivation therapy may effectively reduce tumor size in patients with advanced prostate cancer and LS, indicating a need for more research in this area.
Article Synopsis
- The study examined the effectiveness of enzalutamide combined with immunotherapy in treating non-metastatic castration-sensitive prostate cancer (nmCSPC) without using androgen deprivation therapy (ADT).
- Patients with rising PSA levels were randomized to receive either enzalutamide alone or alongside PROSTVAC, showing significant PSA declines of 99% across both groups.
- Enzalutamide treatment led to immune system changes, including increased natural killer and naïve T cells, and was generally well-tolerated, with the most common side effects being mild fatigue and breast tenderness.
Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the potential to better define characteristics of response and resistance.
View Article and Find Full Text PDFObjective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel.
Patients And Methods: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg).
Background: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S.
View Article and Find Full Text PDFBackground: Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide. The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects.
Methods: A single-arm, open-label, phase 2 study was performed to investigate the disease control rate (DCR) after 2 cycles of veliparib plus temozolomide in patients with metastatic colorectal cancer (mCRC) refractory to all standard therapies.